ATE469151T1 - Pyrrolopyridinderivate als proteinkinaseinhibitoren - Google Patents

Pyrrolopyridinderivate als proteinkinaseinhibitoren

Info

Publication number
ATE469151T1
ATE469151T1 AT06759904T AT06759904T ATE469151T1 AT E469151 T1 ATE469151 T1 AT E469151T1 AT 06759904 T AT06759904 T AT 06759904T AT 06759904 T AT06759904 T AT 06759904T AT E469151 T1 ATE469151 T1 AT E469151T1
Authority
AT
Austria
Prior art keywords
compounds
protein kinase
kinase inhibitors
pyrrolopyridine derivatives
disorders
Prior art date
Application number
AT06759904T
Other languages
English (en)
Inventor
Barun Okram
Pingda Ren
Nathanael S Gray
Original Assignee
Irm Llc
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Scripps Research Inst filed Critical Irm Llc
Application granted granted Critical
Publication of ATE469151T1 publication Critical patent/ATE469151T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
AT06759904T 2005-05-16 2006-05-15 Pyrrolopyridinderivate als proteinkinaseinhibitoren ATE469151T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68185305P 2005-05-16 2005-05-16
PCT/US2006/018868 WO2006124863A2 (en) 2005-05-16 2006-05-15 Pyrrolopyridine derivatives as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE469151T1 true ATE469151T1 (de) 2010-06-15

Family

ID=37076087

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06759904T ATE469151T1 (de) 2005-05-16 2006-05-15 Pyrrolopyridinderivate als proteinkinaseinhibitoren

Country Status (16)

Country Link
US (1) US20080300267A1 (de)
EP (1) EP1896470B1 (de)
JP (1) JP2008540664A (de)
KR (1) KR20080016643A (de)
CN (1) CN101218241B (de)
AT (1) ATE469151T1 (de)
AU (1) AU2006247322A1 (de)
BR (1) BRPI0610828A2 (de)
CA (1) CA2608333A1 (de)
DE (1) DE602006014540D1 (de)
ES (1) ES2345629T3 (de)
MX (1) MX2007014327A (de)
PL (1) PL1896470T3 (de)
PT (1) PT1896470E (de)
RU (1) RU2387653C2 (de)
WO (1) WO2006124863A2 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332940B1 (de) 2004-03-30 2012-10-31 Vertex Pharmaceuticals Incorporated Als Inhibitoren von JAK und anderen Proteinkinasen geeignete Azaindole
KR20070053236A (ko) 2004-07-27 2007-05-23 에스지엑스 파마슈티컬스, 인코포레이티드 융합 고리 헤테로사이클 키나제 조절제
AU2005269386A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
ATE540948T1 (de) * 2005-05-20 2012-01-15 Vertex Pharma Pyrrolopyridine als proteinkinasehemmer
WO2007084557A2 (en) 2006-01-17 2007-07-26 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of janus kinases
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
JP2009537621A (ja) * 2006-05-22 2009-10-29 アストラゼネカ アクチボラグ インドール誘導体
RU2009120622A (ru) * 2006-11-01 2010-12-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Трициклические гетероарильные соединения в качестве ингибиторов янус-киназы
JP5179509B2 (ja) 2006-12-08 2013-04-10 エフ．ホフマン−ラ ロシュ アーゲー 置換ピリミジン類及びｊｎｋモジュレーターとしてのこれらの使用
CN101678022A (zh) * 2006-12-21 2010-03-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
CN101568530A (zh) * 2006-12-22 2009-10-28 诺瓦提斯公司 吲哚-4-基-嘧啶-2-基胺衍生物及其作为细胞周期蛋白依赖性激酶抑制剂的用途
FR2912744B1 (fr) * 2007-02-16 2012-09-07 Centre Nat Rech Scient Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
MX2009010984A (es) 2007-04-10 2010-01-15 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
CL2008001540A1 (es) 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
GB0710528D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
ES2881391T3 (es) * 2007-06-01 2021-11-29 Wyeth Llc Tratamiento de leucemia mielógena crónica resistente a imatinib que tiene la mutación 1457T>C en el gen BcrAbl usando el compuesto bosutinib
DE102007028515A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
CA2704266A1 (en) * 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
AU2009206775A1 (en) * 2008-01-22 2009-07-30 Merck Patent Gmbh Protein kinase inhibitors and use thereof
BRPI0908637B8 (pt) 2008-05-21 2021-05-25 Ariad Pharma Inc composto e composição farmacêutica do mesmo
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
AU2009274011B2 (en) * 2008-07-23 2014-12-18 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
EP2318408B1 (de) * 2008-07-23 2016-02-17 Vertex Pharmaceuticals Incorporated Tricyclische pyrazolopyridin-kinasehemmer
CN101723936B (zh) * 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
CN102459259A (zh) * 2009-05-06 2012-05-16 沃泰克斯药物股份有限公司 吡唑并吡啶类
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN104906100A (zh) * 2009-05-26 2015-09-16 艾伯维巴哈马有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
JP5721706B2 (ja) 2009-06-17 2015-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルス複製の阻害剤
KR101609412B1 (ko) * 2009-07-10 2016-04-05 다이호야쿠힌고교 가부시키가이샤 아자 2 고리형 화합물 또는 그 염
CA2767089A1 (en) * 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
DE102009060175A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
EP2937345B1 (de) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Typ-ii-raf-kinase-hemmer
JP2013518114A (ja) 2010-01-27 2013-05-20 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾロピリミジンキナーゼ阻害剤
CA2787315A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
EP2550272A1 (de) 2010-01-27 2013-01-30 Vertex Pharmaceuticals Incorporated Pyrazolopyrazinkinasehemmer
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
SG10201801794WA (en) 2010-10-29 2018-04-27 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
SG190361A1 (en) 2010-11-23 2013-06-28 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
SI2642999T1 (sl) 2010-11-23 2017-01-31 Abbvie Ireland Unlimited Company Postopki zdravljenja z uporabo selektivnih Bcl-2 inhibitorjev
CN103562205A (zh) * 2010-12-16 2014-02-05 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
WO2012083117A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP2013545817A (ja) * 2010-12-16 2013-12-26 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルス複製阻害物質
EP2704572B1 (de) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Verfahren zur hemmung der zellproliferation bei efgr-vermitteltem krebs
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
US10138235B2 (en) 2011-12-14 2018-11-27 Sanofi Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
EP2809671B1 (de) * 2012-01-30 2016-01-13 Cephalon, Inc. Imidazo[4,5-b]-pyridinderivate als alk- und jak-modulatoren zur behandlung proliferativer erkrankungen
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
US9434725B2 (en) * 2012-06-27 2016-09-06 F. Hoffmann-La Roche Ag 5-azaindazole compounds and methods of use
EP2909194A1 (de) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Hemmer der cyclinabhängigen kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
FR3000493A1 (fr) * 2012-12-28 2014-07-04 Oribase Pharma Nouveaux inhibiteurs de proteines kinases
CA2901155C (en) 2013-03-06 2021-06-08 Allosteros Therapeutics, Inc. Camkii inhibitors and uses thereof
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2014155300A2 (en) * 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
CN105849099B (zh) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 周期蛋白依赖性激酶7(cdk7)的多环抑制剂
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
PT3068782T (pt) 2013-11-13 2018-10-08 Vertex Pharma Métodos de preparação de inibidores da replicação de vírus da gripe
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JP6782227B2 (ja) * 2014-09-05 2020-11-11 ザ・ジョンズ・ホプキンス・ユニバーシティー ＣａＭＫＩＩ阻害剤及びその使用
MA40773A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
MA40772A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3236948A4 (de) * 2014-12-23 2018-10-03 Millennium Pharmaceuticals, Inc. Kombination aus raf-inhibitoren und aurorakinase-inhibitoren
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
EP3294717B1 (de) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Verfahren zur herstellung von inhibitoren der influenzavirenreplikation
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2018269947B2 (en) * 2017-05-15 2021-10-14 The Regents Of The University Of Michigan Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
CN112142731B (zh) * 2019-06-28 2022-07-22 成都赜灵生物医药科技有限公司 一种2，4-二取代嘧啶衍生物及其制备方法和用途
CA3148780A1 (en) * 2019-07-29 2021-02-04 Bent PFAFFENROT Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
CN114452392B (zh) * 2022-02-07 2024-06-18 孙良丹 用于抑制camk2g表达的制剂在制备用于治疗银屑病的药剂中的应用
CN115785134B (zh) * 2022-10-28 2023-08-29 浙大城市学院 一种含氮杂环的硼酸化合物及制备方法和应用
US12269826B1 (en) * 2023-11-16 2025-04-08 King Faisal University 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047899A1 (en) * 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
KR100886161B1 (ko) * 2000-07-11 2009-02-27 파르마 마르, 에스.에이. 항암제로서의 배리올린 유도체
SE0202463D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
EP2332940B1 (de) * 2004-03-30 2012-10-31 Vertex Pharmaceuticals Incorporated Als Inhibitoren von JAK und anderen Proteinkinasen geeignete Azaindole
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders

Also Published As

Publication number Publication date
RU2387653C2 (ru) 2010-04-27
EP1896470A2 (de) 2008-03-12
WO2006124863A2 (en) 2006-11-23
BRPI0610828A2 (pt) 2010-07-27
CN101218241A (zh) 2008-07-09
AU2006247322A1 (en) 2006-11-23
ES2345629T3 (es) 2010-09-28
CN101218241B (zh) 2011-02-16
PT1896470E (pt) 2010-08-26
WO2006124863A3 (en) 2007-01-25
JP2008540664A (ja) 2008-11-20
RU2007146390A (ru) 2009-06-27
DE602006014540D1 (en) 2010-07-08
PL1896470T3 (pl) 2011-03-31
CA2608333A1 (en) 2006-11-23
US20080300267A1 (en) 2008-12-04
EP1896470B1 (de) 2010-05-26
KR20080016643A (ko) 2008-02-21
MX2007014327A (es) 2008-02-11

Similar Documents

Publication Publication Date Title
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
TW200637547A (en) Compounds and compositions as protein kinase inhibitors
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
ATE544761T1 (de) Pyrimidinderivate und zusammensetzungen als c-kit-und pdgfr-kinasehemmer
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
MX2008002165A (es) Compuestos y composiciones como inhibidores de la proteina cinasa.
BRPI0517015A (pt) compostos e composições como inibidores de atividade de receptor 1 de canabinóide
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
WO2004078682A3 (en) Cyclic compounds and compositions as protein kinase inhibitors
CY1115188T1 (el) Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axl
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
TW200801008A (en) Protein kinase inhibitors
ATE482209T1 (de) Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
NO20082880L (no) Inhibitorer av C-MET samt anvendelse derav
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
NO20076659L (no) Pyrrolo(2,3-B)pyridinderivater som protein kinase inhibitorer
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
WO2009097287A9 (en) Compounds and compositions as kinase inhibitors
BRPI0415210A (pt) compostos e composições como inibidores de proteìna cinase
NO20084435L (no) C-MET proteinkinaseinhibitorer
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
MX2009003456A (es) Compuestos y composiciones como inhibidores de proteina cinasa.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1896470

Country of ref document: EP